We hypothesized that the combination therapy of IL‐33 and BTZ could significantly promote the generation of ROS, which induced MM cell death, in addition, excessive ROS accumulation attenuated the NF‐κB activity, thereby decreasing the stemness properties of MM cells. The gene discussed is IL33; the disease is Miyoshi myopathy.